ATHA LeonaBio, Inc.: institutional ownership and insider trading
Over the last 12 months insiders bought $0 and sold $99.4K on the open market.
ATHA revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$19.0M, EPS -0.80
- Quarter ended Mar 31, 2026: revenue n/a, net income −$32.9M, EPS -1.73
- Quarter ended Dec 31, 2025: revenue n/a, net income −$83.3M, EPS -18.90
- Quarter ended Sep 30, 2025: revenue n/a, net income −$6.61M, EPS -1.68
Recent ATHA insider trades
- Mar 4, 2026: Litton Mark James sold 5,156 shares ($27.7K)
- Mar 4, 2026: San Martin Javier sold 1,720 shares ($9.24K)
- Mar 4, 2026: Church Kevin sold 1,359 shares ($7.30K)
- Mar 4, 2026: Worthington Mark sold 1,328 shares ($7.13K)
5%+ owners
- Sermonix Pharmaceuticals, Inc.: 36.9% (Schedule 13D, filed Aug 31, 2026)
- Joseph Edelman: 20.1% (Schedule 13D/A, filed Dec 23, 2025)
- Perceptive Advisors LLC: 20.0% (Schedule 13D/A, filed Aug 25, 2026)
- Anders Hove: 12.1% (Schedule 13G/A, filed Aug 20, 2026)
- Leonard Braden Michael: 7.8% (Schedule 13G/A, filed Feb 14, 2025)
- ADAR1 Capital Management, LLC: 7.7% (Schedule 13G, filed May 15, 2026)
Are insiders buying or selling ATHA?
Over the last 12 months insiders bought $0 and sold $99.4K of LeonaBio, Inc. stock on the open market (SEC Form 4).